Who Owns Halozyme Company?

Who Owns Halozyme Therapeutics?

Understanding the ownership structure of a company like Halozyme Therapeutics is crucial for grasping its strategic direction, influence, and accountability in the dynamic biopharmaceutical landscape. A pivotal event shaping the company's trajectory, such as its initial public offering (IPO) in 2004, marked a significant shift from private funding to public ownership, broadening its stakeholder base and introducing new governance dynamics.

Halozyme Therapeutics, Inc., founded in 1998, is an American biotechnology company headquartered in San Diego, California. The company's founders envisioned developing innovative therapies that target the extracellular matrix to enhance the delivery and efficacy of drugs, particularly in oncology. Halozyme has solidified its position as a leader in the biopharmaceutical industry, recognized for its groundbreaking research and strategic partnerships. As of July 15, 2025, Halozyme Therapeutics boasts a market capitalization of approximately $6.97 billion, with 123 million shares outstanding, reflecting its substantial market presence. The company's innovative approach is exemplified by its work on technologies that can improve drug delivery, such as those that might be analyzed using a Halozyme BCG Matrix.

Delving into Halozyme ownership reveals a complex interplay of institutional investors, management, and individual shareholders. The history of Halozyme ownership shows a progression from early venture capital backing to a predominantly public float. Identifying Halozyme major investors is key to understanding the forces that shape its corporate strategy and future development. The current market capitalization of Halozyme stands as a testament to its growth and market perception.

Institutional investors, such as mutual funds and hedge funds, often hold significant portions of publicly traded companies, and Halozyme Therapeutics is no exception. These large entities can exert considerable influence due to the volume of shares they control. Examining the percentage of Halozyme owned by institutional investors provides insight into the level of confidence these professional money managers have in the company's prospects. Understanding who owns Halozyme is fundamental for anyone looking to assess its stability and growth potential.

The free float of Halozyme stock, which represents the shares available for public trading, is also an important metric. A higher free float generally indicates greater liquidity. For those interested in the company's leadership, it's often relevant to know if the CEO of Halozyme owns company stock, as this can align executive interests with those of other shareholders. The company structure itself is overseen by its Board of Directors, and knowing who the board members of Halozyme Therapeutics are is crucial for understanding corporate governance.

When considering Halozyme shareholders, it's important to look at the largest shareholder of Halozyme Therapeutics to understand who has the most significant stake. The company's journey from its founding by its founders of Halozyme Therapeutics to its current status reflects a dynamic evolution in its ownership. Analyzing how Halozyme's ownership compares to competitors can also offer valuable market context. Furthermore, understanding the insider trading policies at Halozyme is vital for maintaining market integrity and investor confidence.

The question of whether there are any activist investors in Halozyme is also pertinent, as such investors often seek to influence company management to unlock shareholder value. For those seeking detailed information, learning how to find Halozyme ownership records is a practical step. The implications of Halozyme's ownership structure can be far-reaching, impacting everything from strategic decisions to long-term performance. Ultimately, understanding who controls decision making at Halozyme requires a thorough examination of its shareholder base and governance framework.

Halozyme Therapeutics was founded in 1998 by a trio of individuals who brought together scientific, executive, and entrepreneurial expertise. Dr. Gregory Frost, a scientist specializing in protein engineering, was pivotal in establishing the company's core technology. His research focused on enzymes capable of breaking down the extracellular matrix, which became the bedrock of Halozyme's innovative approach to drug delivery.

Dr. Helen Torley, a seasoned executive in the pharmaceutical sector, provided the leadership and strategic direction necessary to guide the company's growth into a significant biopharmaceutical entity. Complementing their efforts, Dr. Jonathan Lim, a physician and entrepreneur, contributed crucial clinical insights and business acumen, steering the company's research and development initiatives.

While the precise initial equity distribution among the founders is not publicly disclosed, their collective vision was to revolutionize drug delivery, particularly for oncology therapies. The company's early strategy centered on leveraging its proprietary recombinant human hyaluronidase enzyme, rHuPH20, for these advancements. A key milestone in its early financial development occurred on March 11, 2004, when Halozyme underwent a recapitalization through a merger with Global. This period also marked its public debut on the Nasdaq stock exchange under the ticker symbol HALO in 2004, a significant step in its journey toward becoming a publicly traded entity and shaping its future Halozyme ownership.

Founding Vision

The founders aimed to improve drug delivery systems through enzymatic technology. Their focus was on enhancing the efficacy and patient experience of various therapies.

Key Technology

The company's foundation was built upon Dr. Gregory Frost's work with enzymes that degrade the extracellular matrix. This technology is central to Halozyme's drug delivery platform.

Leadership Roles

Dr. Helen Torley brought extensive pharmaceutical executive experience, while Dr. Jonathan Lim contributed medical and entrepreneurial expertise. Together, they guided the company's strategic direction.

Early Financial Structuring

A significant event in the company's early financial history was its recapitalization through a merger with Global on March 11, 2004. This set the stage for its public offering.

Public Debut

Halozyme Therapeutics became a publicly traded company in 2004, listing on the Nasdaq stock exchange under the symbol HALO. This marked a new phase in its corporate development and ownership.

Initial Focus

The company's initial efforts were concentrated on developing oncology therapies and drug delivery technologies. The proprietary enzyme rHuPH20 was central to these early endeavors.

Founders and Early Ownership Dynamics

The establishment of Halozyme Therapeutics in 1998 by Dr. Gregory Frost, Dr. Helen Torley, and Dr. Jonathan Lim laid the groundwork for its innovative approach to drug delivery. While specific details regarding initial equity splits are not publicly available, the founders' combined expertise in scientific research, pharmaceutical leadership, and business acumen was instrumental. Their vision was to leverage the company's proprietary recombinant human hyaluronidase enzyme, rHuPH20, to enhance the delivery of various therapeutics, particularly in oncology. The company's strategic recapitalization through a merger with Global on March 11, 2004, and its subsequent public offering on the Nasdaq stock exchange under the symbol HALO in 2004, were critical steps in its early financial structuring and the evolution of its Halozyme ownership landscape. Understanding these foundational elements is key to grasping the history of Halozyme ownership and its subsequent development, including its Marketing Strategy of Halozyme.

• Founding year: 1998
• Key founders: Dr. Gregory Frost, Dr. Helen Torley, Dr. Jonathan Lim
• Proprietary technology: rHuPH20 enzyme
• Recapitalization event: March 11, 2004 (Merger with Global)
• Public listing: 2004 on Nasdaq (Symbol: HALO)
• Initial focus: Oncology therapies and drug delivery

Complete Halozyme Strategy Bundle

• 6 Full Frameworks, 1 Company – All Pre-Researched
• Each Framework Fully Sourced with Real Company Data
• Built for Strategy Courses, Case Studies & MBA Programs
• Adapt to Your Assignment – No Starting from Scratch
• 6 Frameworks: SWOT, PESTLE, Porter's, BMC, BCG and 4P's

GET FULL BUNDLE

The journey of Halozyme Therapeutics began with its public offering in 2004, a pivotal moment that shaped its ownership landscape. Over the years, the company's structure has evolved, reflecting its growth and market position. As of July 14, 2025, Halozyme Therapeutics commands a market capitalization of approximately $7.04 billion, underscoring its significant presence in the biotechnology sector. This valuation is a testament to the company's progress and the confidence investors place in its future. The evolution of Halozyme ownership is largely characterized by the substantial influence of institutional investors.

The majority of Halozyme Therapeutics' stock is held by institutional investors, who collectively own between 60.91% and 84.37% of the company's shares, depending on the specific reporting period. More precisely, as of July 11, 2025, institutional ownership was reported at 71.34%. This significant concentration of ownership among institutions suggests a strong endorsement of the company's strategy and potential. Understanding who owns Halozyme is key to grasping the dynamics of its corporate governance and strategic direction.

Beyond these top holders, other significant institutional investors as of March 31, 2025, include Invesco Ltd., Snyder Capital Management L.P., AllianceBernstein L.P., and Geode Capital Management, LLC. Mutual funds represent a substantial portion of the investor base, holding 47.29% of the company's stock as of March 2025. Furthermore, foreign institutions maintain a notable stake, accounting for 14.55%. Insiders, such as executives and board members, hold a smaller but still relevant 1.11% of the company's stock. This distribution of Halozyme shareholders highlights the significant influence institutional investors wield, impacting corporate decisions and long-term strategy through their substantial voting power and active engagement. The high percentage of Halozyme ownership by institutional investors often signals a mature company with a stable outlook, which can be beneficial for understanding the Target Market of Halozyme.

Key Halozyme Stakeholders

Institutional investors are the dominant force in Halozyme's ownership structure. Their significant stakes influence company direction and governance.

• BlackRock, Inc. is a leading institutional shareholder.
• The Vanguard Group, Inc. also holds a substantial percentage of Halozyme stock.
• State Street Global Advisors, Inc. is another major institutional investor.
• Mutual funds and foreign institutions collectively represent a large portion of ownership.

From PESTLE Factors to Full Strategy Bundle

• PESTLE + SWOT + Porter's + BCG + BMC + 4P's in One Bundle
• Every Strategic Angle Covered – Nothing Left to Research
• Pre-filled with Company-Specific Research
• No Missing Sections for Your Case Study
• One Download Covers Your Entire Company Analysis

GET COMPLETE BUNDLE

The governance of Halozyme Therapeutics is overseen by a classified Board of Directors, structured into three classes. Directors serve staggered three-year terms, ensuring continuity and a blend of experience. For the 2025 Annual Meeting of Stockholders, two Class III directors are slated for election. Key figures on the board include Dr. Helen Torley, who also holds the position of President and CEO, and Jeffrey W. Henderson, a nominee for Class III director with extensive experience in the financial, commercial, and pharmaceutical sectors. Mahesh Krishnan, M.D., joined the board on April 25, 2024, bringing over two decades of expertise in healthcare and biotechnology.

As of the record date of March 4, 2025, Halozyme had 123,533,310 shares of common stock outstanding, with each share carrying one vote. The company's voting structure is based on a one-share-one-vote principle, and there is no public information suggesting the existence of dual-class shares, special voting rights, golden shares, or founder shares that would grant disproportionate control to any specific individual or entity beyond their direct shareholdings. In a notable transition, Connie L. Matsui, a board member for nearly 18 years, announced on February 11, 2025, that she would not seek re-election at the 2025 annual meeting. This decision was amicable and not attributed to any disagreements with the company's operations or strategies, reflecting an ongoing effort to maintain a diverse and expert board composition.

The voting power for Halozyme Therapeutics is primarily distributed among its common stockholders, with each share generally granting one vote. This structure means that significant voting power is typically held by those with the largest stakes in the company. Understanding the distribution of Halozyme ownership is crucial for assessing the influence of various shareholder groups, including institutional investors and individual investors, on corporate decisions. The company's commitment to its Mission, Vision & Core Values of Halozyme is guided by the oversight of its Board of Directors, whose composition and election processes are designed to ensure effective governance.

Understanding Halozyme's Board and Voting Dynamics

The board structure and voting power at Halozyme Therapeutics are key elements in understanding its corporate governance. The upcoming 2025 Annual Meeting will see the election of new directors, impacting the future direction of the company.

• Classified board structure with three-year staggered terms.
• One-share-one-vote system for common stock.
• No indication of disproportionate voting rights for specific shareholders.
• Board composition evolves to ensure diverse expertise.

Halozyme Business Model + Strategy Bundle

• Ideal for Essays, Case Studies & Slides
• Get BCG, SWOT, PESTLE, Porter's, 4P's Mix & BMC Together
• Company-Specific Content Already Organized
• One Bundle Replaces Days of Independent Research
• Buy the Bundle Once. Use Across All Your Assignments

GET COMPLETE ANALYSIS

Over the past few years, Halozyme Therapeutics has experienced significant shifts in its ownership landscape, driven by strategic financial maneuvers and market dynamics. The company has actively engaged in returning capital to its shareholders, a trend that directly influences its ownership structure by reducing the number of outstanding shares.

In February 2024, a substantial $750 million share repurchase program was announced, followed by a new $250 million accelerated share repurchase (ASR) program initiated in January 2025. The completion of the first $250 million ASR in March 2025 and the announcement of a second $250 million share repurchase in May 2025 underscore this commitment. These actions are designed to potentially enhance earnings per share and signal confidence in the company's valuation, impacting the percentage of ownership held by various investor groups.

The ownership of Halozyme Therapeutics is characterized by a strong presence of institutional investors, indicating sustained confidence in the company's strategic direction and financial performance. As of July 14, 2025, a significant number of institutional owners, totaling 1097, collectively held 154,030,090 shares. Prominent among these major investors are BlackRock, Inc., Vanguard Group Inc, and State Street Corp, which are consistently among the largest holders of publicly traded companies. This high level of institutional ownership suggests that a substantial portion of Halozyme's stock is managed by professional investment firms, which often have a long-term investment horizon.

Institutional Investor Dominance

A significant majority of Halozyme's shares are held by institutional investors. As of July 14, 2025, over 1000 institutions owned more than 154 million shares. This concentration reflects strong external validation of the company's strategy and market position.

Key Institutional Holders

Major financial institutions like BlackRock, Vanguard, and State Street are among the largest Halozyme shareholders. Their substantial holdings indicate a belief in the company's growth prospects and its ability to generate shareholder value.

Share Repurchase Programs

Halozyme has been actively repurchasing its own stock, with programs totaling hundreds of millions of dollars announced and executed between early 2024 and mid-2025. These buybacks reduce the number of outstanding shares, potentially increasing ownership percentages for remaining shareholders and boosting earnings per share.

Strategic Acquisition Attempts

The company explored a significant acquisition in late 2024, aiming to diversify its revenue streams ahead of patent expirations for its core technology. Although the bid was withdrawn, it signaled an ongoing strategy to pursue growth through mergers and acquisitions, which could reshape its ownership structure in the future.

From Five Forces to Full Company Analysis

• Includes SWOT, PESTLE, BMC, BCG and 4P's
• Pre-Researched with Company-Specific Data
• Best Value for a Complete Analysis
• Ready to Adapt for Your Case Study
• Ready for Essays and Slidesd

GET FULL BUNDLE